Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NEW YORK, March 07, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired common stock of ReWalk Robotics Ltd. (“ReWalk”) (NASDAQ:RWLK) pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014.
You are hereby notified that a securities action Deng, et al. v. ReWalk Robotics, Ltd., et al. (Case No. 1:17-cv-10169) has commenced in the USDC for the District Massachusetts. If you purchased or otherwise acquired ReWalk common stock pursuant to the Offering, your rights may be affected by this action. To get more information go to: zlk.9nl.com/rewalk-robotics-rwlk.
The complaint alleges that the Registration Statement and Prospectus issued in connection with the Initial Public Offering failed to disclose material information, including that ReWalk was unprepared and/or unable to comply with “special controls” requirements or to provide the U.S. Food and Drug Administration with a postmarket surveillance study as required by the FDA for the Company to maintain ongoing sales of its products.
If you suffered a loss in ReWalk you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
